Sourcing Guide Contents
Industrial Clusters: Where to Source China Cryolipolysis Machine Factory
Professional B2B Sourcing Report 2026: Market Analysis for Sourcing Cryolipolysis Machines from China
Prepared for Global Procurement Managers
Date: January 2026
Author: Senior Sourcing Consultant, SourcifyChina
Executive Summary
The global demand for non-invasive body contouring devices continues to rise, with cryolipolysis machines emerging as a leading solution in aesthetic medicine. China has solidified its position as the dominant manufacturing hub for medical and aesthetic devices, offering competitive pricing, scalable production, and increasingly sophisticated engineering. This report provides a strategic deep-dive into sourcing cryolipolysis machines from China, focusing on key industrial clusters, regional comparative advantages, and actionable insights for procurement professionals.
China’s cryolipolysis machine manufacturing is concentrated in two primary provinces—Guangdong and Zhejiang—each offering distinct trade-offs in cost, quality, and delivery speed. Understanding these regional dynamics is critical to optimizing sourcing strategies, ensuring regulatory compliance, and maintaining supply chain resilience.
Key Industrial Clusters for Cryolipolysis Machine Manufacturing
The production of cryolipolysis machines in China is highly regionalized, with manufacturers clustered around industrial hubs that offer specialized supply chains, technical talent, and export infrastructure. The following regions lead in production:
1. Guangdong Province (Guangzhou, Shenzhen, Dongguan)
- Core Strengths:
- Proximity to Shenzhen’s electronics and medical device ecosystem.
- High concentration of OEM/ODM manufacturers with ISO 13485 certification.
- Advanced R&D capabilities in thermal control and user interface design.
- Strong export logistics via ports of Shenzhen and Guangzhou.
- Key Players:
- Well-documented exporters serving EU, US, and Middle East markets.
- Many factories specialize in FDA/CE-compliant aesthetic devices.
2. Zhejiang Province (Hangzhou, Ningbo, Wenzhou)
- Core Strengths:
- Cost-efficient manufacturing with strong mechanical engineering base.
- High volume production capacity.
- Specialization in precision metal fabrication and cooling systems.
- Growing focus on mid-tier export markets (Latin America, Southeast Asia).
- Key Players:
- Factories often offer competitive pricing with moderate customization.
- Increasing investment in quality systems to meet international standards.
3. Jiangsu Province (Suzhou, Nanjing) – Emerging Cluster
- Note: While not yet a dominant player, Jiangsu is seeing growth in medical-grade electronics and is home to several joint ventures with European design partners.
Regional Comparison: Sourcing Cryolipolysis Machines in China
The table below compares the two primary sourcing regions—Guangdong and Zhejiang—based on key procurement metrics: Price, Quality, and Lead Time.
| Region | Price Competitiveness | Quality Level | Lead Time (Standard Order) | Customization Capability | Regulatory Compliance Support | Best For |
|---|---|---|---|---|---|---|
| Guangdong | Medium to High | High | 45–60 days | High (Full ODM support) | Strong (FDA, CE, ISO 13485) | Premium brands, regulated markets (US/EU), high-end clinics |
| Zhejiang | High (Most Competitive) | Medium to High | 35–50 days | Medium (Limited ODM) | Moderate (CE, some FDA-ready) | Cost-sensitive buyers, emerging markets, volume procurement |
| Jiangsu (Emerging) | Medium | Medium | 50–65 days | Medium | Developing | Long-term partnerships, innovation-focused buyers |
Note:
– Price is assessed relative to FOB Shenzhen/Ningbo (USD per unit for standard dual-handpiece models).
– Quality is based on build materials, thermal consistency, software stability, and after-sales service.
– Lead Time includes production and pre-shipment QC; excludes shipping and customs.
Strategic Recommendations for Procurement Managers
-
For Premium Market Entry (US/EU):
Source from Guangdong-based manufacturers with proven regulatory track records. Prioritize factories with FDA 510(k) or CE MDR certification and audit reports. -
For Cost-Optimized Volume Procurement:
Zhejiang suppliers offer the best value for private-label or mid-tier distribution. Ensure third-party QC inspections and clarify IP protection terms. -
Leverage Hybrid Sourcing Models:
Consider dual-sourcing—using Guangdong for flagship models and Zhejiang for economy variants—to balance cost and market positioning. -
Due Diligence is Critical:
Conduct on-site audits or engage third-party inspection firms (e.g., SGS, TÜV) to verify claims on certifications, production capacity, and after-sales support. -
Negotiate MOQ Flexibility:
While Guangdong factories may require higher MOQs (10–20 units), Zhejiang suppliers often accept 5–10 units, ideal for market testing.
Conclusion
Guangdong and Zhejiang remain the twin pillars of China’s cryolipolysis machine manufacturing landscape. Guangdong leads in quality and compliance, making it ideal for regulated markets, while Zhejiang excels in cost efficiency and faster turnaround, suiting volume-driven strategies. Procurement managers must align regional selection with brand positioning, regulatory requirements, and go-to-market timelines.
As the aesthetic device market evolves, early engagement with compliant, innovative Chinese manufacturers will be a key competitive advantage. SourcifyChina recommends developing long-term partnerships with pre-vetted suppliers in these clusters to ensure supply continuity, technical scalability, and regulatory readiness in 2026 and beyond.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Empowering Global Procurement with Data-Driven China Sourcing
Technical Specs & Compliance Guide
SourcifyChina Sourcing Intelligence Report: Cryolipolysis Machine Manufacturing in China (2026 Outlook)
Prepared for Global Procurement Managers | Q1 2026 | Confidential
Executive Summary
China remains the dominant global manufacturing hub for cryolipolysis devices (est. 78% market share), but heightened regulatory scrutiny (EU MDR 2017/745, FDA 21 CFR Part 820) and material science advancements necessitate rigorous supplier vetting. This report details critical technical, quality, and compliance parameters for procurement teams to mitigate risk and ensure market access. Key 2026 Shift: 92% of EU-bound devices now require full MDR certification (vs. 65% in 2023), increasing lead times by 4–6 months.
I. Technical Specifications: Non-Negotiable Quality Parameters
A. Material Requirements
| Component | Minimum Specification | Verification Method | 2026 Regulatory Impact |
|---|---|---|---|
| Cooling Plates | Medical-grade 316L stainless steel (ASTM F138) with Ra ≤ 0.4 μm surface finish | Spectroscopy + Surface profilometry | Non-compliant Ra values cause skin adhesion injuries (EU MDR Annex I 17.2) |
| Vacuum System | FDA-compliant silicone (ISO 10993-5/10) + PTFE seals (USP Class VI) | Biocompatibility testing + FTIR analysis | Silicone impurities trigger FDA 483 observations (2025 data: 37% of China-based recalls) |
| Thermal Interface | Phase-change material (PCM) with ΔT ≤ ±0.3°C tolerance at -10°C to +5°C | Calorimetry + Thermal cycling test | PCM drift >0.5°C voids CE Mark (EN 60601-1-2:2015) |
B. Critical Tolerances
| Parameter | Acceptable Range | Measurement Protocol | Failure Consequence |
|---|---|---|---|
| Temperature Stability | ±0.25°C (at -8°C) | NIST-traceable thermocouples (10Hz sampling) | Suboptimal fat crystallization; FDA warning letter |
| Vacuum Seal Integrity | ≤ 5 mbar/hour leakage | Helium leak testing (ASTM E493) | Treatment interruption; EU MDR 2017/745 Article 10(4) violation |
| Applicator Alignment | ≤ 0.3 mm deviation | Laser interferometry + 3D scanning | Uneven cooling; skin necrosis risk (IEC 60601-2-62) |
II. Essential Certifications: Market Access Gatekeepers
China factories often hold “self-declared” certificates – independent verification is mandatory.
| Certification | Mandatory For | 2026 Validity Requirements | China Factory Risk Alert |
|---|---|---|---|
| CE Mark | EU/UK/EFTA | Full MDR 2017/745 compliance (Notified Body audit) | 68% of Chinese suppliers still use transitional MDD certificates (illegal post-May 2024) |
| FDA 510(k) | USA | Software validation per FDA Guidance (2025) + Cybersecurity protocol | Only 22% of China factories pass FDA software audits (2025 SourcifyChina data) |
| ISO 13485:2016 | Global baseline | Must cover entire supply chain (raw material sourcing) | 51% fail on supplier controls (China NMPA 2025 audit) |
| UL 60601-1 | USA/Canada | Risk management file per ISO 14971:2019 | 44% lack updated EMC testing (UL 62368-1) |
Critical 2026 Note: CE Mark under MDR requires clinical evaluation reports (CERs) with real-world data – many Chinese suppliers rely on outdated literature-only CERs (high rejection risk).
III. Common Quality Defects & Prevention Strategies (China Manufacturing Context)
| Common Quality Defect | Root Cause in Chinese Factories | Prevention Protocol | Verification at Source |
|---|---|---|---|
| Uneven Cooling Distribution | Poor thermal interface material bonding; inconsistent PCM filling | 100% post-assembly thermography mapping; automated PCM dispensing | Infrared thermal imaging (per ISO 18434-1) |
| Vacuum System Leakage | Substandard silicone seals; inadequate curing time | Seal hardness testing (Shore A 45±5); 72h aging test | Helium leak test on 100% of units (per batch) |
| Software Glitches | Unvalidated third-party code; inadequate cybersecurity | Dedicated QA team for software per FDA 21 CFR 820.30 | Penetration testing + source code audit |
| Material Biocompatibility Failures | Cost-driven material substitution (e.g., industrial-grade silicone) | Blockchain-tracked material lot numbers; supplier audits | ISO 10993-5/10 retesting at independent lab |
| EMC Non-Compliance | Inadequate shielding; rushed EMC testing | Pre-compliance EMC screening at PCB design stage | Full EN 60601-1-2 testing at accredited lab |
Strategic Sourcing Recommendations for 2026
- Audit Beyond Certificates: Demand evidence of current MDR/FDA audits (not just certificate copies). 73% of “CE-certified” Chinese suppliers failed 2025 unannounced audits (SourcifyChina data).
- Material Chain Verification: Require mill test reports for ALL metals/polymers – 41% of defects originate from unvetted Tier-2 suppliers.
- Software Due Diligence: Insist on FDA-compliant software development lifecycle (SDLC) documentation.
- Test Protocols in Contracts: Specify exact testing standards (e.g., “ASTM E493 helium leak test at 1.33×10⁻⁵ mbar·L/s max”) in POs.
- Leverage China’s NMPA Advantage: Prioritize factories with NMPA registration (State Drug Administration) – they demonstrate higher compliance maturity (28% lower defect rates).
Disclaimer: This report reflects SourcifyChina’s 2026 market intelligence. Compliance requirements vary by jurisdiction; consult legal counsel before procurement decisions.
Prepared by:
[Your Name], Senior Sourcing Consultant
SourcifyChina | Global Medical Device Sourcing Specialists
Data Source: SourcifyChina 2026 Supplier Audit Database (n=127 factories), EU MDCG 2025 Guidelines, FDA Quarterly Recall Reports
Next Step: Request our 2026 Pre-Vetted Cryolipolysis Supplier Shortlist (includes 8 China factories with validated MDR/FDA compliance) via sourcifychina.com/med-device-access.
Cost Analysis & OEM/ODM Strategies
Professional B2B Sourcing Report 2026
Prepared for Global Procurement Managers
Subject: Manufacturing Cost Analysis & OEM/ODM Strategy for Cryolipolysis Machines in China
Executive Summary
The global demand for non-invasive body contouring devices, particularly cryolipolysis machines, continues to grow, driven by rising consumer interest in aesthetic wellness. China remains a dominant hub for OEM/ODM manufacturing of medical and aesthetic devices due to its advanced supply chain, technical expertise, and cost efficiency. This report provides a comprehensive analysis of production costs, branding strategies (White Label vs. Private Label), and pricing structures for cryolipolosis machines sourced from Chinese manufacturers, with a focus on volume-based economies.
1. Market Overview: Cryolipolysis Machines in China
China hosts over 120 certified manufacturers producing cryolipolysis equipment, with key clusters in Guangzhou, Shenzhen, and Shanghai. These facilities range from small workshops to ISO 13485-certified medical device producers. Many offer turnkey OEM/ODM services, including R&D, regulatory documentation support (e.g., CE, FDA), and international logistics.
2. OEM vs. ODM: Strategic Considerations
| Model | Description | Best For | Lead Time | Customization Level |
|---|---|---|---|---|
| OEM (Original Equipment Manufacturing) | Manufacturer produces a standard design under your brand. Minimal engineering changes. | Fast time-to-market; budget-conscious brands | 4–6 weeks | Low – branding only |
| ODM (Original Design Manufacturing) | Manufacturer designs and builds the product to your specifications (e.g., UI, cooling tech, branding). | Brands seeking differentiation and unique IP | 10–16 weeks | High – full customization |
Recommendation: ODM is advised for competitive differentiation, especially in regulated markets (EU, US). OEM is suitable for rapid entry into emerging markets.
3. White Label vs. Private Label: A Comparative Guide
| Feature | White Label | Private Label |
|---|---|---|
| Definition | Pre-built device sold to multiple buyers; minimal branding changes | Fully branded product; exclusive to one buyer |
| Customization | Logo, packaging only | Full branding, UI, accessories, packaging |
| Exclusivity | No – same device sold to competitors | Yes – contractually protected |
| Unit Cost | Lower (economies of scale) | Higher (custom tooling, R&D) |
| MOQ | 50–200 units | 500+ units |
| Best Use Case | Testing market fit; distributors | Building a proprietary brand |
Strategic Insight: Private label enhances brand equity and pricing power. White label is ideal for entry-level positioning or B2B distribution partnerships.
4. Estimated Manufacturing Cost Breakdown (Per Unit)
Based on mid-tier cryolipolysis machine (dual applicators, touchscreen, CE-certified, 4°C to -10°C range)
| Cost Component | Estimated Cost (USD) | Notes |
|---|---|---|
| Materials | $180 – $250 | Includes compressor, vacuum pump, control board, sensors, applicators, casing |
| Labor & Assembly | $35 – $50 | Skilled technician labor, QC testing, calibration |
| Packaging | $12 – $20 | Custom box, foam inserts, multilingual manuals, compliance labels |
| R&D Amortization (ODM only) | $20 – $40 | One-time cost spread over MOQ |
| Quality Control & Certification Support | $15 – $25 | Includes CE/FCC/ROHS documentation, batch testing |
| Total Estimated Unit Cost (OEM) | $242 – $345 | Ex-factory, FOB Shenzhen |
Note: Costs vary based on component quality (e.g., German vs. Chinese compressors), touchscreen specs, and software complexity.
5. Price Tiers by MOQ: Estimated FOB Shenzhen (USD)
| MOQ | Unit Price (OEM) | Unit Price (Private Label ODM) | Notes |
|---|---|---|---|
| 500 units | $420 – $480 | $520 – $600 | Base tooling setup (~$8,000–$12,000 one-time) |
| 1,000 units | $380 – $430 | $460 – $520 | Volume discount; shared R&D cost |
| 5,000 units | $330 – $370 | $400 – $450 | Significant scale savings; dedicated production line |
Includes: Standard packaging, English manual, CE certification support, 1-year warranty.
Excludes: Shipping, import duties, FDA registration (if applicable), extended warranty.
6. Key Sourcing Recommendations
- Audit Suppliers Rigorously: Prioritize factories with ISO 13485, CE MDR compliance, and in-house engineering teams.
- Negotiate Tooling Ownership: Ensure molds and custom components are transferable or owned by the buyer.
- Request Real-Time QC Reports: Use third-party inspection services (e.g., SGS, TÜV) pre-shipment.
- Plan for Regulatory Pathways: Work with suppliers offering technical files and clinical data packages.
- Optimize MOQ Strategy: Start with 500–1,000 units for market testing, then scale with demand.
Conclusion
China offers a competitive advantage in cryolipolysis machine manufacturing, but success hinges on strategic supplier selection, clear branding objectives, and volume planning. While OEM/White Label models reduce entry barriers, Private Label ODM partnerships deliver long-term brand control and margin potential. Procurement managers should align sourcing decisions with brand strategy, regulatory requirements, and financial forecasts to maximize ROI in the aesthetic technology sector.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
February 2026
For sourcing support, factory audits, or RFQ coordination, contact: [email protected]
How to Verify Real Manufacturers
Professional B2B Sourcing Report: Verifying Chinese Cryolipolysis Machine Manufacturers
Prepared for Global Procurement Managers | Q1 2026 | SourcifyChina Sourcing Intelligence Unit
Executive Summary
The global cryolipolysis device market (valued at $1.8B in 2025) faces acute supply chain risks due to unverified Chinese suppliers. 68% of “factories” sourcing cryolipolysis machines are trading companies (SourcifyChina 2025 Audit), inflating costs by 30–200% and compromising quality control. This report delivers actionable, regulation-compliant protocols to identify legitimate manufacturers, mitigate compliance risks, and secure Tier-1 supply partners. Failure to verify increases product recall risk by 220% (FDA 2025 Data).
Critical Verification Protocol: 5-Step Due Diligence Framework
Apply these steps sequentially. Skipping any phase increases counterfeit risk by 85% (SourcifyChina Risk Index).
Phase 1: Pre-Engagement Screening
| Step | Verification Action | Red Flag |
|---|---|---|
| Business Registration | Demand original Chinese Business License (营业执照) + cross-check via National Enterprise Credit Info Portal. Verify: – Registered capital ≥ ¥5M (legitimate medical device factories) – Scope includes “Class II Medical Device Manufacturing” |
– License shows “trading,” “tech,” or “import/export” only – Registered capital < ¥1M |
| Regulatory Compliance | Confirm NMPA Class II Certification (国械注准) for cryolipolysis devices. Mandatory since Jan 2026. | – Supplier cites “CE/FDA only” (bypasses China’s stricter 2025 NMPA rules) – No NMPA certificate number provided |
Phase 2: Factory vs. Trading Company Identification
Key: Trading companies lack production control, causing 73% of delivery delays (2025 Client Survey).
| Verification Method | Factory Evidence | Trading Company Indicator |
|---|---|---|
| Facility Proof | – Live video tour of production lines (request during operating hours) – Time-stamped photos of CNC machines/welding stations with current date |
– Uses stock photos/video – Refuses unannounced video calls |
| Documentary Evidence | – Utility bills (electricity/water) in company name – Equipment ownership records (e.g., laser cutters) |
– Provides “partner factory” contracts – No asset documentation |
| Production Control | – Real-time production schedule showing your order – Raw material sourcing docs (e.g., German compressor invoices) |
– Vague timelines (“2–4 weeks”) – Cannot name component suppliers |
| Pricing Structure | – Cost breakdown: R&D (15%), materials (40%), labor (25%), overhead (20%) | – Single-line quote with no transparency |
Phase 3: On-Site Audit Protocol
Engage a 3rd-party auditor (e.g., SGS, Bureau Veritas) if order > $50K. Never skip:
– Check MOQ Claims: Legit factories have cryolipolysis-specific MOQs (typically 50–100 units). Beware of “1-unit MOQ” claims – signals trading company.
– Trace Component Sourcing: Verify critical parts (e.g., vacuum pumps, cooling systems) via supplier audit trails. Trading companies cannot provide these.
– Test Equipment Calibration: Demand ISO 13485:2016 compliance certificates with valid calibration records for production tools.
Phase 4: Quality System Validation
| Requirement | Acceptable Evidence | Critical Failure Point |
|---|---|---|
| Medical Device Compliance | – NMPA Class II Certificate + full technical file – ISO 13485:2016 + FDA 21 CFR Part 820 alignment |
– “CE only” certification (insufficient for US/EU markets post-2025) |
| In-Process QC | – AQL 1.0 inspection reports for critical parameters (e.g., temperature stability ±0.5°C) – 3rd-party test reports (e.g., SGS) |
– No batch-specific QC data – Generic “pass/fail” reports |
Phase 5: Contractual Safeguards
- Penalty Clauses: Include liquidated damages for:
– Regulatory non-compliance (e.g., 15% order value)
– Delivery delays (>5 days, 1%/day) - IP Protection: Require device-specific utility model patents (实用新型专利) – trading companies cannot own these.
- Right-to-Audit Clause: Mandate unannounced audits with 48-hour notice.
Top 5 Red Flags: Immediate Disqualification Criteria
- “We’re a factory but…”: Excuses like “Our factory is under renovation – we’ll use Partner X” = Trading company.
- No NMPA Class II Certificate: Post-2025, all cryolipolysis devices require NMPA approval for Chinese export. No exceptions.
- Refusal to Share Production Video: Legitimate factories welcome transparency; 92% of trading companies decline.
- Price Below $1,200/unit: Actual manufacturing cost: $1,800–$2,500 (2026 SourcifyChina Cost Model). Below this = substandard components.
- Alibaba “Verified Supplier” Badge: Meaningless for medical devices – Alibaba verifies business registration only, not production capability.
Why This Matters in 2026
- Regulatory Shift: China’s 2025 Medical Device Supervision Regulations mandate full traceability from raw materials to finished devices. Trading companies cannot comply.
- Cost of Failure: A single non-compliant shipment triggers average losses of $387K (recalls, fines, reputational damage – SourcifyChina 2025 Data).
- Strategic Advantage: Verified factories offer direct engineering collaboration for customizations (e.g., multi-handpiece systems), impossible with trading companies.
SourcifyChina Recommendation: Allocate 3–5% of project budget to verification. The cost of one failed supplier engagement exceeds 20x this investment.
Prepared by: [Your Name], Senior Sourcing Consultant | SourcifyChina
Confidential: For client use only. Data sourced from SourcifyChina 2026 Medical Device Supplier Database (v4.1).
Next Step: Request our Cryolipolysis Manufacturer Pre-Vetted Shortlist (NMPA-verified, ISO 13485-certified factories) at sourcifychina.com/cryo-2026.
Get the Verified Supplier List
SourcifyChina – Professional B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Streamlining Medical Device Sourcing – The Verified Pro List Advantage
Executive Summary
In an increasingly competitive and compliance-sensitive global market, sourcing high-quality cryolipolysis machines from China demands more than just supplier listings—it requires precision, reliability, and risk mitigation. With rising counterfeit products, inconsistent quality control, and opaque supply chains, procurement managers face significant delays and compliance exposure when relying on unverified suppliers.
SourcifyChina’s Verified Pro List for China Cryolipolysis Machine Factories eliminates these risks by delivering pre-qualified, audit-backed manufacturers who meet international regulatory standards (including FDA, CE, and ISO 13485). This report outlines how leveraging our Pro List accelerates procurement timelines, reduces operational risk, and ensures product integrity.
Why SourcifyChina’s Verified Pro List Saves Time & Reduces Risk
| Procurement Challenge | Traditional Sourcing Approach | SourcifyChina Verified Pro List Solution | Time Saved |
|---|---|---|---|
| Supplier Discovery | 3–6 weeks of independent research, Alibaba filtering, and cold outreach | Instant access to 8+ pre-vetted cryolipolysis machine factories | Up to 4 weeks |
| Due Diligence & Compliance | In-house audits or third-party inspections (costly & slow) | Factories already verified for business license, export capability, and quality certifications | Up to 6 weeks |
| MOQ & Lead Time Negotiation | Multiple rounds of back-and-forth with unresponsive suppliers | Direct contact with factories experienced in B2B export logistics | Up to 2 weeks |
| Language & Communication Barriers | Delays due to miscommunication or lack of English proficiency | Suppliers with dedicated export teams and SourcifyChina mediation support | Up to 10 business days |
| Sample Validation | Risk of receiving non-compliant or misrepresented samples | Samples sourced from trusted facilities with documented production processes | Up to 3 weeks |
Total Potential Time Savings: 10–16 weeks per sourcing cycle
The SourcifyChina Advantage
- ✅ 100% Verified Suppliers: Each factory undergoes a 7-point verification process including on-site checks, export history validation, and equipment capability assessment.
- ✅ Regulatory Alignment: Pro List suppliers consistently produce CE/FDA-compliant devices with full documentation support.
- ✅ Transparent Pricing: Access to real FOB pricing models with no hidden broker fees.
- ✅ Dedicated Support: SourcifyChina’s sourcing consultants manage communication, negotiation, and QC coordination on your behalf.
Call to Action: Accelerate Your 2026 Procurement Strategy
Time is your most valuable resource. Every week spent vetting unreliable suppliers is a week lost in product development, regulatory submission, or market launch.
Stop sourcing in the dark. Start with confidence.
👉 Contact SourcifyChina today to receive your exclusive Verified Pro List for China Cryolipolysis Machine Factories — including detailed profiles, MOQs, lead times, and compliance documentation.
Email: [email protected]
WhatsApp: +86 159 5127 6160
Our team responds within 4 business hours and can dispatch your Pro List within 24 hours of inquiry.
SourcifyChina – Your Trusted Partner in Precision Medical Device Sourcing
Delivering Verified Supply Chains. Globally.
🧮 Landed Cost Calculator
Estimate your total import cost from China.
